176 related articles for article (PubMed ID: 27725536)
21. Renal amyloidosis is associated with increased mortality in hemodialysis patients.
Sengul S; Arat Z; Ozdemir FN
Artif Organs; 2004 Sep; 28(9):846-52. PubMed ID: 15320948
[TBL] [Abstract][Full Text] [Related]
22. Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study.
Asai S; Fujibayashi T; Oguchi T; Hanabayashi M; Hayashi M; Matsubara H; Ito T; Yabe Y; Watanabe T; Hirano Y; Kanayama Y; Kaneko A; Kato T; Takagi H; Takahashi N; Funahashi K; Takemoto T; Asai N; Watanabe T; Ishiguro N; Kojima T
Mod Rheumatol; 2018 Mar; 28(2):221-226. PubMed ID: 28701065
[TBL] [Abstract][Full Text] [Related]
23. Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study.
Aaltonen KJ; Virkki LM; Jämsen E; Sokka T; Konttinen YT; Peltomaa R; Tuompo R; Yli-Kerttula T; Kortelainen S; Ahokas-Tuohinto P; Blom M; Nordström DC
Semin Arthritis Rheum; 2013 Aug; 43(1):55-62. PubMed ID: 23481417
[TBL] [Abstract][Full Text] [Related]
24. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
25. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
[TBL] [Abstract][Full Text] [Related]
26. Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry.
Park DJ; Choi SJ; Shin K; Kim HA; Park YB; Kang SW; Kwok SK; Kim SK; Nam EJ; Sung YK; Lee J; Lee CH; Jeon CH; Lee SS
Clin Rheumatol; 2017 May; 36(5):1013-1022. PubMed ID: 28243760
[TBL] [Abstract][Full Text] [Related]
27. Depression is improved when low-dose tacrolimus is given to rheumatoid arthritis patients showing an inadequate response to biologic agents.
Miwa Y; Hosaka M; Ohtsuka K; Sato M; Takahashi R; Wakabayashi K; Odai T; Yajima N; Kasama T
Mod Rheumatol; 2013 Sep; 23(5):920-4. PubMed ID: 22990336
[TBL] [Abstract][Full Text] [Related]
28. Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: a real-world study.
Lampropoulos CE; Orfanos P; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
Clin Exp Rheumatol; 2017; 35(2):192-200. PubMed ID: 28094760
[TBL] [Abstract][Full Text] [Related]
29. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis.
Nakamura T
Mod Rheumatol; 2008; 18(2):109-18. PubMed ID: 18369528
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes and survival in AA amyloidosis patients.
Ayar Y; Ersoy A; Oksuz MF; Ocakoglu G; Vuruskan BA; Yildiz A; Isiktas E; Oruc A; Celikci S; Arslan I; Sahin AB; Güllülü M
Rev Bras Reumatol Engl Ed; 2017; 57(6):535-544. PubMed ID: 29173691
[TBL] [Abstract][Full Text] [Related]
31. End-stage renal disease in patients with rheumatoid arthritis.
Paudyal S; Yang FM; Rice C; Chen CC; Skelton M; Bethel M; Brown S; Nahman NS; Carbone L
Semin Arthritis Rheum; 2017 Feb; 46(4):418-422. PubMed ID: 27591827
[TBL] [Abstract][Full Text] [Related]
32. Remission of proteinuria and preservation of renal function in patients with renal AA amyloidosis secondary to rheumatoid arthritis.
Ueno T; Takeda K; Nagata M
Nephrol Dial Transplant; 2012 Feb; 27(2):633-9. PubMed ID: 21771754
[TBL] [Abstract][Full Text] [Related]
33. Amyloidosis and rheumatoid arthritis.
Husby G
Clin Exp Rheumatol; 1985; 3(2):173-80. PubMed ID: 3893817
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis.
Nakamura T; Yamamura Y; Tomoda K; Tsukano M; Shono M; Baba S
Clin Rheumatol; 2003 Dec; 22(6):371-5. PubMed ID: 14677008
[TBL] [Abstract][Full Text] [Related]
35. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P; Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
[TBL] [Abstract][Full Text] [Related]
36. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Ohnishi A; Kabata D; Hirano T; Hara R; Katayama M; Yoshida S; Nagai K; Son Y; Amuro H; Akashi K; Fujimura T; Hirao M; Yamamoto K; Shintani A; Kumanogoh A; Yoshikawa H
PLoS One; 2018; 13(3):e0194130. PubMed ID: 29543846
[TBL] [Abstract][Full Text] [Related]
37. Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis.
Smith GR; Tymms KE; Falk M
Intern Med J; 2004; 34(9-10):570-2. PubMed ID: 15482271
[TBL] [Abstract][Full Text] [Related]
38. Serum level of reactive oxygen metabolites (ROM) at 12 weeks of treatment with biologic agents for rheumatoid arthritis is a novel predictor for 52-week remission.
Nakajima A; Aoki Y; Sonobe M; Takahashi H; Saito M; Nakagawa K
Clin Rheumatol; 2017 Feb; 36(2):309-315. PubMed ID: 27858176
[TBL] [Abstract][Full Text] [Related]
39. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
[TBL] [Abstract][Full Text] [Related]
40. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
